Avalo Therapeutics, Inc.
General ticker "AVTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $89.4M (TTM average)
Avalo Therapeutics, Inc. follows the US Stock Market performance with the rate: 47.6%.
Estimated limits based on current volatility of 6.7%: low 15.76$, high 18.04$
Factors to consider:
- Total employees count: 19 as of 2023
- Top business risk factors: Insufficient funding, Unsuccessful programs, Regulatory and compliance, Product development risks, Labor/talent shortage/retention
- Current price 11.3% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.15$, 16.12$]
- 2025-12-31 to 2026-12-31 estimated range: [2.99$, 10.45$]
Financial Metrics affecting the AVTX estimates:
- Negative: with PPE of -0.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -69.80 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
Short-term AVTX quotes
Long-term AVTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $18.05MM | $1.92MM | $0.44MM |
| Operating Expenses | $55.49MM | $29.27MM | $68.95MM |
| Operating Income | $-37.44MM | $-27.35MM | $-68.51MM |
| Non-Operating Income | $-4.19MM | $-4.18MM | $33.50MM |
| Interest Expense | $4.17MM | $3.42MM | $0.00MM |
| R&D Expense | $31.31MM | $13.78MM | $52.08MM |
| Income(Loss) | $-41.63MM | $-31.53MM | $-35.02MM |
| Taxes | $0.03MM | $0.01MM | $0.11MM |
| Profit(Loss)* | $-41.66MM | $-31.54MM | $-35.13MM |
| Stockholders Equity | $-10.91MM | $7.30MM | $133.03MM |
| Inventory | $0.02MM | $0.00MM | $0.00MM |
| Assets | $33.37MM | $20.99MM | $150.73MM |
| Operating Cash Flow | $-26.75MM | $-30.68MM | $-49.06MM |
| Capital expenditure | $0.10MM | $0.16MM | $0.00MM |
| Investing Cash Flow | $-0.10MM | $-0.13MM | $0.36MM |
| Financing Cash Flow | $-14.70MM | $25.04MM | $175.85MM |
| Earnings Per Share** | $-1,062.65 | $-113.58 | $-4.32 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.